X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The financing aims to fund the HOOKIPA investigational product HB-500, which is a 2-vector arenaviral therapeutic vaccine. It is currently under evaluation as a component of a potential curative regimen for HIV infections.
Lead Product(s): HB-500
Therapeutic Area: Infections and Infectious Diseases Product Name: HB-500
Highest Development Status: IND EnablingProduct Type: Vaccine
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: $21.2 million Upfront Cash: Undisclosed
Deal Type: Financing December 21, 2023
Details:
HB-500 is an alternating, 2-vector novel arenaviral therapeutic vaccine which is under clinical development for the treatment of human immunodeficiency virus (HIV).
Lead Product(s): HB-500
Therapeutic Area: Infections and Infectious Diseases Product Name: HB-500
Highest Development Status: IND EnablingProduct Type: Vaccine
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2023
Details:
HB-200 is HOOKIPA’s lead oncology candidate engineered with the its proprietary replicating arenaviral vector platform. HB-200 in combination with pembrolizumab received Fast Track Designation for the treatment of 1st-line recurrent/metastatic HPV16+ head and neck cancers.
Lead Product(s): HB-200,Pembrolizumab
Therapeutic Area: Oncology Product Name: HB-200
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2023
Details:
HB-400 (GS-2829) is an alternating, 2-vector non-replicating arenaviral therapeutic vaccine which uses the lymphocytic choriomeningitis virus and pichinde virus as arenaviral backbones,for the treatment of chronic hepatitis B.
Lead Product(s): GS-2829,GS-6779
Therapeutic Area: Infections and Infectious Diseases Product Name: HB-400
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2023
Details:
The collaboration between HOOKIPA and Roche is to license and develop HB-700, a novel arenaviral immunotherapy for KRAS-mutated cancers and an option for a second, undisclosed arenaviral immunotherapy. HOOKIPA is conducting research through Phase 1b for HB-700.
Lead Product(s): HB-700
Therapeutic Area: Oncology Product Name: HB-700
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: $955.0 million Upfront Cash: $25.0 million
Deal Type: Collaboration February 13, 2023
Details:
Following the submission of the clinical trial application (IND equivalent) for HB-400, a Hepatitis B therapeutic, in 2022, HOOKIPA expects the first patient to be dosed in a Phase 1 clinical trial during 2023.
Lead Product(s): HB-400
Therapeutic Area: Infections and Infectious Diseases Product Name: HB-400
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: $410.0 million Upfront Cash: $10.0 million
Deal Type: Collaboration January 04, 2023
Details:
HOOKIPA will conduct development, based on its proprietary arenavirus platform, through Phase 1b for HB-700, an arenaviral immunotherapy for treatment of KRAS-mutated cancers and option to license a second undisclosed novel arenaviral immunotherapy.
Lead Product(s): HB-700
Therapeutic Area: Oncology Product Name: HB-700
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: $955.0 million Upfront Cash: $25.0 million
Deal Type: Collaboration October 20, 2022
Details:
HB-300 is alternating, 2-vector replicating arenaviral immunotherapy for castration-resistant prostate cancer, uses Lymphocytic Choriomeningitis Virus and Pichinde Virus as arenaviral backbones, with each expressing two well-defined antigens of prostate cancer, PAP and PSA.
Lead Product(s): HB-300
Therapeutic Area: Oncology Product Name: HB-300
Highest Development Status: IND EnablingProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 25, 2022
Details:
HB-200 was generally well tolerated, rapidly induced a high magnitude of tumor-specific T cells and showed early anti-tumor activity in these difficult-to-treat patients.
Lead Product(s): HB-200
Therapeutic Area: Oncology Product Name: HB-200
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2022
Details:
Novel arenaviral therapeutic HB-200 generates outstanding tumor antigen-specific CD8+ T cell responses (average of 6 percent and up to 40 percent of T cell pool).
Lead Product(s): HB-200
Therapeutic Area: Oncology Product Name: HB-200
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
